Omel

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Omel

Omel is a highly effective medicine used to reduce stomach acid, belonging to a modern class of drugs called Proton Pump Inhibitors (PPIs). It is typically a prescription-required (Rx) medicine, although the active ingredient is widely available in lower-dose, over-the-counter preparations.


Quick Facts

Property Description
Active Ingredient Omeprazole
Form Delayed-release capsules, Delayed-release tablets
Pharmacological Class Proton Pump Inhibitor (PPI)
General Purpose Suppression of gastric acid secretion
Origin Synthetic organic compound

What Type of Medicine is Omel and What is it Made Of?

Omel is a medicinal preparation whose active component is the synthetic organic compound Omeprazole, chemically classified as a substituted benzimidazole. Pharmacologically, Omeprazole is a Proton Pump Inhibitor (PPI), functioning as a powerful antisecretory compound that provides long-lasting acid reduction. PPIs, including Omeprazole, are recognized for their effectiveness in controlling gastric acid production compared to other acid therapies. This means the medicine is reliable for reducing the amount of acid the stomach makes.


What is the General Purpose and Form of Omel?

The primary general purpose of Omel is to achieve sustained suppression of gastric acid secretion in the upper gastrointestinal tract. By reducing acid output, the medicine helps to alleviate the common symptoms and discomfort associated with acid-related hypersecretion, a typical use scenario being the relief of frequent heartburn. Omel is typically presented in an oral dosage form as an enteric-coated, delayed-release capsule or tablet. This specialized pharmaceutical design is necessary because the active ingredient, Omeprazole, is fragile and would be degraded by the high acidity of the stomach. The delayed-release formulation protects the drug until it can be absorbed effectively, ensuring the intended therapeutic effect of the medicine is achieved after ingestion.

Regulatory References

  1. Omeprazole Delayed-Release FDA Labeling

What side effects are possible with Omel?

Possible Side Effects and Safety Information

Omel (Omeprazole) is associated with officially documented adverse reactions that are categorized by their frequency of occurrence, as defined by regulatory standards (e.g., EMA/FDA). These reactions span multiple body systems, offering a structured understanding of the medicine's safety profile.

Adverse Reaction Classifications

The most frequent adverse reactions generally involve the gastrointestinal and nervous systems. These are organized according to regulatory frequency terminology:

Frequency Category Examples of Officially Listed Side Effects
Common (ge 1/100) Headache, Abdominal pain, Diarrhea, Flatulence, Nausea, Vomiting, Constipation.
Uncommon (ge 1/1,000) Insomnia, Dizziness, Paresthesia, Increased liver enzymes, Rash, Urticaria, Malaise.
Rare (ge 1/10,000) Leukopenia, Thrombocytopenia, Hypersensitivity reactions (e.g., Angioedema), Confusion, Hepatitis, Hair loss (Alopecia), Arthralgia, Myalgia.

Serious and Duration-Related Safety Notes

The regulatory profile highlights several serious adverse reactions, which are rare but clinically significant. These include severe skin reactions (e.g., Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis), Agranulocytosis, Tubulointerstitial Nephritis, and Anaphylactic Shock.

Specific risks are tied to the duration of use. Prolonged exposure (typically exceeding one year) is associated with an increased risk of Hypomagnesemia (low magnesium levels), Bone Fracture (hip, wrist, or spine), and Cyanocobalamin (Vitamin B-12) Deficiency. Furthermore, the risk of C. difficile-associated diarrhea is officially noted to occur during or after treatment with the drug.

Safety limitations include a contraindication for individuals with hypersensitivity to Omeprazole or related compounds. Regulatory documents also note that the medicine may interfere with diagnostic tests (e.g., Chromogranin A levels) and advise caution in patients with severe hepatic impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

Regulatory labeling for Omeprazole (Omel) documents that overdosage may be associated with a range of transient clinical manifestations. These presentations have been officially reported in cases involving doses up to 900 mg. The documented signs of overdosage are variable and may involve the central nervous system and autonomic systems. Specific symptoms listed in regulatory sources include confusion, drowsiness, and blurred vision, alongside physical signs such as tachycardia (increased heart rate), nausea, diaphoresis (increased sweating), flushing, headache, and dry mouth.

Regarding severity, regulatory authorities describe these symptoms as transient, and no serious clinical outcome has been officially reported in association with Omeprazole overdosage.

However, if overdosage is suspected, the official mandate is to seek emergency medical attention or contact the Poison Help line immediately. This action is required because no specific antidote for Omeprazole overdosage is known.

Treatment must therefore be symptomatic and supportive. Regulatory information also notes that Omeprazole is not readily removed by hemodialysis due to its extensive protein binding. There are no specific population-based overdose considerations detailed in the official regulatory sections.

Therapeutic Uses of Omel

What Omel Treats: Main Uses and Benefits

Omel is used for managing certain distressing symptoms that interfere with daily functioning. This medication is applied across domains where additional symptomatic support is needed in the management of conditions presenting with systemic or localized discomfort. Specifically, this medication is used to treat symptoms of GERD, a condition where acid backs up from the stomach and can cause injury to the esophagus.

The medication is commonly used to help with groups of symptoms that may appear suddenly or fluctuate, including the burning pain of frequent heartburn, the discomfort of peptic ulcers in the stomach or upper intestine, and the symptoms of erosive esophagitis (acid-related esophageal damage). It is relevant when symptoms are related to inflammatory or irritative states.

Relief for Heartburn

Omel may assist with easing the overall symptom load associated with persistent acid backing up, supporting general well-being during symptomatic phases.

It is applied in clinical settings that involve acute or unstable symptom patterns. One of the main patient benefits is that the medication supports patients during episodes of heightened discomfort and may help patients cope more steadily with symptom fluctuations. This assists with maintaining functional stability and provides supportive relief when symptoms interfere with routine activities.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Omel (Omeprazole) is a Proton Pump Inhibitor whose use is strictly governed by regulatory eligibility criteria based on patient population, age, and existing conditions. It is contraindicated and must not be used by patients with a known hypersensitivity to omeprazole, substituted benzimidazoles, or any formulation component. Patients receiving the antiretroviral medicine nelfinavir are also officially contraindicated for co-administration.

Age and Physiological Status

Population Group Regulatory Status
Adults & Older Adults Use is established; routine dose adjustment is not needed for older adults.
Infants (< 1 year of age) Safety and effectiveness are not established for all indications.
Pregnant Patients Use is conditional: allowed only if the benefit outweighs the potential risk.
Breastfeeding Mothers Use is not recommended as the drug may pass into human milk.

Condition-Based Eligibility

Patients with impaired hepatic function may require that a lower daily dose be considered due to increased exposure. Renal impairment does not typically require a dose adjustment. Importantly, the possibility of gastric malignancy must be excluded by a healthcare professional when using Omel for symptoms suggestive of a gastric ulcer.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Omel's official interaction profile is defined by its two main effects: inhibiting the enzyme CYP2C19 and suppressing gastric acid. These mechanisms dictate necessary restrictions and special timing conditions for co-administration with other medicines, as documented in regulatory labeling.

Official Interaction Restrictions

Restriction Type Interacting Substances Regulatory-Described Outcome
Formal Contraindication Nelfinavir Significantly reduced Nelfinavir plasma concentration, compromising efficacy.
Discouraged Co-use Clopidogrel Decreased exposure to the active Clopidogrel metabolite (via CYP2C19 inhibition).

Omeprazole is classified as an inhibitor of the enzyme CYP2C19, which can lead to increased plasma concentrations of co-administered CYP2C19 substrates, including Diazepam and Phenytoin. The acid-suppressing effect also alters the absorption of medicines, resulting in reduced exposure for certain HIV antivirals (e.g., Atazanavir, Rilpivirine) and increased exposure for drugs like Digoxin.

Timing and Substance-Related Cautions

Long-term, daily use of Omel may result in reduced absorption of Cyanocobalamin (Vitamin B12). Co-administration with the herbal product St. John's Wort or the drug Rifampin leads to decreased plasma exposure of Omeprazole itself. A period of at least five days without Omeprazole is required before measuring Chromogranin A (CgA) levels, as the drug interferes with the diagnostic test.

Mechanism of Action

Irreversible Blockade of the Proton Pump

Omel's active ingredient acts as a pro-drug that is selectively activated within the acidic environment of the gastric parietal cells. It then forms a stable, covalent bond with the mathbfH^+/mathbfK^+- ATPase enzyme, or Proton Pump, which represents the final common step in gastric acid secretion. This irreversible inhibition permanently blocks the transport of hydrogen ions, resulting in the sustained suppression of intragastric acidity.


Duration Governed by Cellular Renewal

The resulting cessation of acid production is prolonged because the return of full acid secretion capacity is not determined by the drug's elimination from the body, but by the physiological rate at which the parietal cells synthesize and incorporate new, functional Proton Pump enzymes. This cellular-dependent mechanism determines the pharmacological duration of the antisecretory action and accounts for the time required to reach steady-state maximal inhibition of the H^+/ K^+- ATPase pool.

Dosage and Administration Information

Instruction Map: How to use Omel

Omel (Omeprazole) usage is characterized by specific protocols regarding administration route, dosage, and timing, emphasizing the drug's unique delayed-release formulation.

Administration Scope

The primary route of administration is oral, encompassing delayed-release capsules, tablets, and oral suspension. An intravenous (IV) route is also used for the active substance in clinical settings when oral intake is not feasible.

Feature Standard Parameters
Dosing schedule A typical adult dose for symptomatic GERD is 20 mg once daily. The treatment dose for Gastric Ulcer is higher, at 40 mg once daily. For Pathological Hypersecretory Conditions, the initial dose is 60 mg once daily, with total daily doses exceeding 80 mg requiring divided administration.
Timing in relation to meals Oral formulations must be taken before eating, generally specified as before the morning meal.
Special procedural conditions The delayed-release capsules must be swallowed whole and must not be crushed or chewed to protect the active substance from stomach acid. For patients with swallowing difficulties, the pellets can be administered with a small amount of specified food, such as applesauce.
Course duration Treatment for acute conditions is typically 4 to 8 weeks. The non-prescription use for frequent heartburn is officially limited to a 14-day course.

Population Rules and Frequency

Dosing is adjusted for patients with severe hepatic impairment (often reduced to 10 mg to 20 mg once daily). Pediatric dosing for approved indications is calculated by body weight. Most regimens adhere to a once daily frequency, with twice daily reserved only for high-dose hypersecretory conditions or combination therapies. If a dose is missed, standard protocols involve taking it immediately unless less than 12 hours remain before the next dose, in which case the missed dose is skipped; doses are not doubled.

Recent Clinical Evidence

Research evidence / Overview of Studies for Omel

Research Evidence for Common Acid-Related Symptoms (GERD and Esophagitis)

Research exploring Omel for common acid-related symptoms, such as frequent heartburn associated with GERD, mainly draws on findings from short-term Randomized Controlled Trials (RCTs). These studies were designed to measure changes in patient-reported outcomes, specifically tracking the frequency, intensity, and duration of symptoms. Studies explored whether patients achieved a symptom-free status and how outcomes related to overall daily functioning were measured.

For erosive esophagitis (damage to the lining of the esophagus from acid), research explored the measurement of endoscopic healing in study cohorts. Studies reported patterns indicating that measured healing of ulcers was documented in a proportion of patients over the measured short-term study period (typically 4 to 8 weeks). The evidence structure in this area includes multiple well-structured trials, often designated as being composed primarily of Randomized Controlled Trials (RCTs).


Research Evidence for Peptic Ulcers and H. pylori Eradication

Omel was studied for peptic ulcers located in the stomach or the upper intestine. For treating ulcers linked to Helicobacter pylori bacteria, Omel was evaluated in studies as part of a triple therapy—a combination regimen used to eradicate H. pylori. Research was designed to measure the bacteriological outcome, or the rate of successful bacterial elimination. Findings reported patterns suggesting that the rate of ulcer recurrence was monitored in cohorts where bacterial elimination was documented.


Evidence in Key Patient Populations and Gaps

Omel was studied for use in specific demographic groups, most notably pediatric patients (children). These trials often involved smaller groups and shorter observation periods compared to the main adult studies. The findings contribute to the broader evidence landscape describing how the medicine was evaluated in these distinct cohorts, but data for certain groups remain insufficient to draw broad conclusions.

Authoritative reviews indicate several areas where the research evidence remains limited or where certainty remains low. There is limited information for long-term outcomes, especially for patients requiring continuous use over many years for common conditions, as the follow-up durations were limited in many controlled trials. Furthermore, for certain indications or subgroups, comparative evidence is lacking to fully determine how Omel performed directly against every single newer acid-reducing medicine in consistent trials.

Frequently Asked Questions (FAQ)

Common questions about Omel (FAQ)

Q: How quickly can a person expect Omel to start working?

The anti-secretory effect is described in official documents as generally beginning within one hour after administration, reaching its peak effectiveness around two hours. For non-prescription use, official labeling indicates that the full measure of relief for frequent heartburn may take between one to four days to be realized. Some symptom relief may be noted within the first 24 hours of starting treatment.


Q: How long after stopping Omel do its effects usually last?

Omel works by forming a stable bond with the proton pump enzyme responsible for acid production. Because of this mechanism, the acid-suppressing effect is prolonged. The return of full acid secretion capacity depends on the physiological rate at which the stomach cells create new proton pump enzymes, not just when the drug leaves the body.


Q: Is it necessary to take Omel on an empty stomach?

Official regulatory guidance states that the delayed-release capsules are to be taken before a meal, usually in the morning. This is necessary because the active ingredient is fragile and can be destroyed by stomach acid. The administration timing is designed to ensure the specialized coating protects the drug until it can be absorbed properly.


Q: Is Omel meant for short-term treatment or is long-term use common?

The duration of treatment is defined by the condition being treated. Use for acute, prescription conditions is generally described in official documents as 4 to 8 weeks. For frequent heartburn treated without a prescription, use is strictly limited to a 14-day course, which should not be repeated more often than once every four months.


Q: Is Omel ever prescribed for use in children?

Official documents confirm that Omel is approved for treating certain acid-related conditions in pediatric patients. Approvals cover children from 1 year to 16 years of age for conditions like GERD, and it is also approved for infants as young as 1 month to less than 1 year for healing erosive esophagitis. Dosing for these groups is described as being calculated based on body weight.


Q: Does Omel interfere with the absorption of iron supplements?

Studies and official information indicate that Omel’s acid-reducing effect may impair the body’s absorption of nonheme iron. This is because the process relies on an acidic environment that the drug suppresses. This effect may result in a reduced response to standard oral iron replacement therapy for people with iron deficiency.


Q: What are the safety considerations for people with renal impairment?

Regulatory documents note that Omel is associated with adverse kidney outcomes, including tubulointerstitial nephritis and acute kidney injury. Official labeling states that patient monitoring is recommended for signs such as a decrease in urine output.


Q: Can Omel cause diarrhea, and when should a person be concerned about it?

Diarrhea is listed as a common side effect of Omel. Official safety information, however, notes that its use is associated with an increased risk of a more serious condition called Clostridium difficile-associated diarrhea (CDAD). This risk is noted to be associated with persistent diarrhea that does not improve.


Q: Does Omel affect mood or cause feelings of anxiety?

Rare psychiatric reactions listed in official documents include confusion, aggression, depression, and hallucinations. Postmarketing reports from regulatory bodies have also included mentions of anxiety and agitation in relation to the drug.


Q: What are fundic gland polyps, and are they related to taking Omel?

Taking PPIs like Omel, especially for an extended time (typically one year or longer), may lead to the development of small growths on the stomach lining called fundic gland polyps. These polyps are generally documented as being benign, with the highest risk noted with high doses and long duration of use.


Q: Are there any known food or dietary interactions with Omel?

There are no known direct pharmacokinetic interactions between the drug itself and most foods, but the capsules must be taken before eating as directed. Regulatory labeling specifies that certain specialized formulations can be administered with a small amount of specific foods, like applesauce, for patients with swallowing difficulties.


Q: Does the use of Omel prevent the stomach from making acid permanently?

No, the medicine achieves long-lasting acid suppression through the irreversible inhibition of the proton pump enzyme. However, the effect is not permanent. Full acid secretion capacity returns when the stomach cells synthesize and incorporate new, functional enzymes, a process that occurs over time.


Q: Is it safe to drive or operate machinery while taking Omel?

Omel will generally not affect a person's ability to drive or operate machinery. However, regulatory warnings advise that if a person experiences specific side effects such as dizziness or vision problems, it is recommended to wait until these effects have passed before driving or operating machinery.


Q: What are the signs of a serious allergic reaction to Omel?

Serious hypersensitivity reactions are possible, including Anaphylactic Shock and Angioedema, which is severe swelling of tissues. Symptoms noted in regulatory summaries that have been associated with serious reactions include trouble breathing or swallowing, itching, or severe swelling of the face, hands, or mouth.


Q: What is the purpose of the enteric coating on Omel capsules?

The active ingredient, Omeprazole, is highly fragile and would be destroyed by the natural acidity of the stomach. The enteric coating is a special design that ensures the drug remains intact while in the stomach. This allows the medication to dissolve and be absorbed effectively in the small intestine to achieve its full therapeutic effect.


Q: Can Omel cause a dry mouth or increased thirst?

Dry mouth is listed as a potential adverse reaction in regulatory postmarketing experience reports. Official safety documentation does not explicitly list increased thirst as a reported side effect of the drug.

How should Omel be stored and disposed of?

Storage and Disposal Conditions for Omel (Omeprazole)

Omel must be stored under specific conditions to maintain the stability of the Omeprazole active ingredient, as defined by regulatory authorities.


Storage Requirements

The medicine must be kept at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). It is essential to protect Omel from moisture and store it away from high heat. The product should remain in its original container and be kept tightly closed. As with all medicines, Omel must be stored out of the sight and reach of children.


Disposal Instructions

To dispose of expired or unused Omel, follow local requirements. The FDA recommends utilizing official drug take-back programs when available. If a take-back program is not accessible, the product should be mixed with an undesirable substance (like dirt) and sealed in a container before being placed in the household trash. Omel should generally not be flushed down a toilet or poured down a sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Omel found in:

A-Z Index: